Study on the Safety of Intraoperative Rhatitrexide Intraperitoneal Perfu-sion Chemotherapy in Patients with Peritoneal Metastasis of Colorectal Cancer
Objective To analyze the safety of intraoperative rhatitrexide intraperitoneal chemotherapy in patients with peritoneal metastasis of colorectal cancer.Methods A total of 120 patients with peritoneal metastasis of colorectal can-cer admitted to the Central Hospital of Shan County from March 2021 to October 2023 were randomly selected as the study objects,and were divided into the reference group(n=60)and the observation group(n=60)according to the dif-ferent treatment methods.Reference group underwent laparoscopic radical resection of colorectal cancer,and the ob-servation group received intra-abdominal perfusion chemotherapy with rhatitrexed during the operation on the basis of the reference group.The incidence of immune function,postoperative complications and adverse reactions before and after operation were compared between the two groups.Results Before operation,there was no significant difference in immune function between the two groups(P>0.05).The immune function of both groups was improved 3 days after op-eration,and CD4+in observation group was(55.61±2.20)%,which was higher than(50.89±2.14)%in reference group.CD8+in the observation group was(36.09±1.52)%,which was lower than(39.04±1.61)%in the reference group,CD4+/CD8+in the observation group was(1.28±0.20),which was higher than(1.15±0.23)in the reference group,and the dif-ferences were statistically significant(t=11.912,10.320,3.304,all P<0.05).There was no significant difference in the incidence of postoperative complications and adverse reactions between two groups(both P>0.05).Conclusion In the surgical treatment of patients with peritoneal metastasis of colorectal cancer,intra-abdominal perfusion chemotherapy with raltitrexel can reduce the effect of surgery on immune function,has a good therapeutic safety,and does not signifi-cantly increase the occurrence of adverse reactions.
万方数据
维普
